We have located links that may give you full text access.
Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials.
Introduction: This meta-analysis was conducted to evaluate efficacy and safety in patients treated with sorafenib vs other tyrosine-kinase inhibitors (TKIs) or selective internal radiotherapy (SIRT) for advanced hepatocellular carcinoma (HCC).
Methods: Electronic databases were systematically reviewed for randomized Phase III trials comparing sorafenib with other TKIs or SIRT in advanced HCC. Sorafenib was defined as the control arm. Other TKIs or SIRT was defined as the experimental arm. Overall survival (OS), time to progression (TTP), objective response rate (ORR), disease-control rate (DCR), and adverse events (AEs) were reviewed. Four trials in the other-TKI group (n=4,218) and two in the SIRT group (n=819) were eligible.
Results: Compared with sorafenib, other TKIs showed similar benefit on OS (HR 1.08, 95% CI 0.93-1.24; P =0.31) and TTP (HR 0.86, 95% CI 0.66-1.12; P =0.26) for advanced HCC. A significant increase in ORR (RR 1.67, 95% CI 1.15-2.43; P =0.008) was found with other TKIs, but no increase in DCR (RR 1.11, 95% CI 0.98-1.26; P =0.11) was observed. Other TKIs were associated with more frequent grade 3/4 AEs than sorafenib, including hypertension ( P <0.00001), thrombocytopenia ( P =0.002), fatigue ( P <0.00001), decreased appetite ( P <0.00001), and vomiting ( P <0.0001). For locally advanced HCC, neither OS (HR 1.14, 95% CI 0.98-1.32; P =0.09) nor TTP (HR 0.87, 95% CI 0.74-1.02; P =0.10) differed significantly in SIRT and sorafenib. There was an increase in ORR (RR 2.60, 95% CI 1.69-4.00; P <0.0001), but no improvement in DCR (RR 0.91, 95% CI 0.81-1.02; P =0.11) in the SIRT group. Fewer patients treated with SIRT had grade 3/4 AEs than those treated with sorafenib, including diarrhea ( P <0.0001), fatigue ( P =0.0006), and hand-foot syndrome ( P =0.0002). Other TKIs were noninferior to sorafenib in OS and TTP in advanced HCC, but with increased risk of toxicities.
Conclusion: Patients with locally advanced HCC treated with SIRT got similar efficacy with less toxicity to those treated with sorafenib.
Methods: Electronic databases were systematically reviewed for randomized Phase III trials comparing sorafenib with other TKIs or SIRT in advanced HCC. Sorafenib was defined as the control arm. Other TKIs or SIRT was defined as the experimental arm. Overall survival (OS), time to progression (TTP), objective response rate (ORR), disease-control rate (DCR), and adverse events (AEs) were reviewed. Four trials in the other-TKI group (n=4,218) and two in the SIRT group (n=819) were eligible.
Results: Compared with sorafenib, other TKIs showed similar benefit on OS (HR 1.08, 95% CI 0.93-1.24; P =0.31) and TTP (HR 0.86, 95% CI 0.66-1.12; P =0.26) for advanced HCC. A significant increase in ORR (RR 1.67, 95% CI 1.15-2.43; P =0.008) was found with other TKIs, but no increase in DCR (RR 1.11, 95% CI 0.98-1.26; P =0.11) was observed. Other TKIs were associated with more frequent grade 3/4 AEs than sorafenib, including hypertension ( P <0.00001), thrombocytopenia ( P =0.002), fatigue ( P <0.00001), decreased appetite ( P <0.00001), and vomiting ( P <0.0001). For locally advanced HCC, neither OS (HR 1.14, 95% CI 0.98-1.32; P =0.09) nor TTP (HR 0.87, 95% CI 0.74-1.02; P =0.10) differed significantly in SIRT and sorafenib. There was an increase in ORR (RR 2.60, 95% CI 1.69-4.00; P <0.0001), but no improvement in DCR (RR 0.91, 95% CI 0.81-1.02; P =0.11) in the SIRT group. Fewer patients treated with SIRT had grade 3/4 AEs than those treated with sorafenib, including diarrhea ( P <0.0001), fatigue ( P =0.0006), and hand-foot syndrome ( P =0.0002). Other TKIs were noninferior to sorafenib in OS and TTP in advanced HCC, but with increased risk of toxicities.
Conclusion: Patients with locally advanced HCC treated with SIRT got similar efficacy with less toxicity to those treated with sorafenib.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app